Drug Profile
Research programme: cancer vaccines - Canopus BioPharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Canopus BioPharma
- Class Cancer vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 04 Nov 2008 Canopus BioPharma's cancer vaccine is available for co-development licensing in the US (http://www.canopusbiopharma.com)
- 04 Nov 2008 Preclinical trials in Solid tumours in USA (Parenteral)